Hutchison China MediTech’s (HCM’s) investment case is focused on evolution into a global R&D and commercial-stage biopharma company with a marketed portfolio of innovation-led oncology drugs. 2020 is a golden year as HCM moves towards multiple domestic drug launches and is progressing key assets into registration studies globally. We expect surufatinib (NET) and savolitinib (exon 14 deletion NSCLC) China launches in 2020 and 2021, respectively, following in the footsteps of El
24 Mar 2020
Hutchison China MediTech - From innovation to oncology commercialization
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hutchison China MediTech - From innovation to oncology commercialization
HUTCHMED (China) Limited (HCM:LON) | 267 -2.7 (-0.4%) | Mkt Cap: 2,326m
- Published:
24 Mar 2020 -
Author:
Dr Susie Jana -
Pages:
14
Hutchison China MediTech’s (HCM’s) investment case is focused on evolution into a global R&D and commercial-stage biopharma company with a marketed portfolio of innovation-led oncology drugs. 2020 is a golden year as HCM moves towards multiple domestic drug launches and is progressing key assets into registration studies globally. We expect surufatinib (NET) and savolitinib (exon 14 deletion NSCLC) China launches in 2020 and 2021, respectively, following in the footsteps of El